Annual report pursuant to Section 13 and 15(d)

License Agreements (Narrative) (Details)

v3.19.1
License Agreements (Narrative) (Details) - USD ($)
1 Months Ended 12 Months Ended
Oct. 25, 2016
Jun. 30, 2016
Nov. 19, 2013
Jul. 31, 2011
Apr. 30, 2011
Feb. 28, 2011
Jun. 30, 2009
Apr. 30, 2009
Dec. 31, 2018
Dec. 31, 2010
Dec. 31, 2017
May 30, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Sep. 08, 2010
Additional consideration               $ 12,500                      
Minimum royalty payment for first three years, per year                   $ 10,000             $ 10,000 $ 10,000  
Minimum royalty payment for remainer life of agreement, per year                 $ 20,000   $ 20,000   $ 20,000 $ 20,000 $ 20,000 $ 20,000      
Milestone payment                     1,000 $ 500,000              
Milestone payment upon annual net sales of $100,000,000 or more                         250,000            
Option fees                                     $ 2,000
Exercise of stock options       $ 10,000                              
Maintenance fee $ 82,000                                    
Upfront fee $ 20,000                                    
Pelican Therapeutics, Inc. [Member]                                      
Minimum royalty payment for first three years, per year                   10,000             10,000 $ 10,000  
Minimum royalty payment for remainer life of agreement, per year                 20,000   20,000   20,000 20,000 20,000 20,000      
License agreement ("SS114A") [Member]                                      
Reimbursement of for past patent fees           $ 37,381                          
License Agreement ("143") [Member]                                      
Reimbursement of for past patent fees           50,000                          
License Agreement ("J110") [Member]                                      
Reimbursement of for past patent fees           10,000                          
License Agreement for Multiple Myeloma [Member]                                      
Maintenance fee                 5,000                    
License 0331, 0539 [Member] | Pelican Therapeutics, Inc. [Member]                                      
Milestone payments due upon submission                 150,000                    
Milestone payments completion of phase 1 clinical trial                 250,000                    
License I176 [Member] | Pelican Therapeutics, Inc. [Member]                                      
Minimum royalty payment for first three years, per year                             $ 10,000 $ 10,000 $ 10,000    
Minimum royalty payment for remainer life of agreement, per year                 20,000   $ 20,000   $ 20,000 $ 20,000          
License Costs                   50,000                  
Reimbursement of for past patent fees                   $ 15,797                  
Milestone payments due upon submission                 150,000                    
Milestone payments completion of phase 1 clinical trial                 $ 500,000                    
UMM143 [Member] | Pelican Therapeutics, Inc. [Member]                                      
License Costs     $ 35,000                                
Not For Profit Corporation Fee Two [Member]                                      
License Costs         $ 50,000                            
Patents [Member] | License Agreement ("143") [Member]                                      
License Costs           14,158                          
Patents [Member] | License Agreement ("J110") [Member]                                      
License Costs           $ 1,055                          
SubsidiaryOneMember | Not For Profit Corporation Fee Two [Member]                                      
Percentage of issued and outstanding stock owned             7.50%                        
Shattuck Labs, Inc. ("Shattuck") Member                                      
License Costs   $ 50,000